Burning Rock Biotech Limi... (BNR)

NasdaqGM: BNR · 실시간 가격 · USD

9.78

-1.11 (-10.19%)

종가 기준: Aug 21, 2026, 8:00 PM

9.78

+0.00%

애프터마켓: 7:30 PM

주가와 핵심 숫자, 최신 뉴스를 한 곳에 모았습니다.

-10.19% (1D)

데이터 없음

매수호가	6.35
시가총액	103.14M
매출 (ttm)	514.43M
순이익 (ttm)	-59.32M
	1.38
	-0.83
	n/a
	-16.86
P/B (ttm)	1.34
P/S (ttm)	0.20
실적 발표일	n/a

매도호가	11.48
거래량	4,518
평균 거래량 (20일)	18,453
시가	9.40
전일 종가	10.89
일중 범위	9.11 - 10.25
52주 범위	6.79 - 41.72
애널리스트	n/a
목표주가	n/a
배당	n/a
배당락일	n/a

BNR 소개

Burning Rock Biotech Limited develops and sells cancer therapy selection tests in the People's Republic of China and the United States. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company offers next-generation sequencing (NGS)-based tissue, liquid biopsy cancer therapy selection, and prognosis prediction tests for various cancer types, including lung cancer, ...

[더 보기]

산업 Diagnostics & Research

섹터 Healthcare

IPO 일자 Jun 12, 2020

직원 수 667

상장 거래소 NasdaqGM

티커 BNR

웹사이트 https://www.brbiotech.com

전체 기업 정보

재무 실적

2025년 Burning Rock Biotech의 매출은 539.57M로, 전년 515.82M 대비 4.6% 증가했습니다. 순이익은 -55.35M로, -84.03% 감소했습니다.

재무제표

어닝 서프라이즈

Burning Rock Biotech가 May 30, 2023에 분기 실적을 발표했습니다:

매출 $107.94M 예상치 하회 $0, 및 -18.89% 전년 대비 감소.
EPS -18.1 예상치 하회 -4.20, 및 27.60% 전년 대비 성장.

뉴스

2주 전 · Simply Wall St.

Myriad Genetics (MYGN) Missed Q2 And Cut Guidance, Is It Still 54% Below Fair Value?

Myriad Genetics (MYGN) is back in focus after its second quarter 2026 earnings missed expectations and the company cut its full year revenue guidance, moves that triggered a sharp selloff in the stock...

3주 전 · Simply Wall St.

Myriad Genetics (MYGN) Is Down 49.0% After Cutting 2026 Revenue Outlook Amid Prenatal Test Weakness

In late July 2026, Myriad Genetics reported second-quarter 2026 results showing sales of US$190.7 million and a reduced net loss of US$43.2 million, while also lowering full-year 2026 revenue guidance...

5개월 전 · MarketBeat

Brenntag Q4 Earnings Call Highlights

Brenntag (ETR:BNR) executives said fiscal 2025 played out against one of the most prolonged downturns in the chemical industry in decades, with market conditions deteriorating as the year progressed a...

9개월 전 · Barchart

This Undiscovered Biotech Stock Has Quintupled in a Year and Just Hit New Highs

Burning Rock Biotech (BNR) , a precision oncology company from China, has shown exceptional technical momentum and price appreciation. BNR has surged 405% over the past year, hitting a 2-year high on ...